Business
COEGIN: First commercial revenues achieved and liquidity strengthened, with expansion planned for 2026
COEGIN: First commercial revenues achieved and liquidity strengthened, with expansion planned for 2026
About this update from Coegin Pharma Ab
Transitioned to a commercial platform with first revenues from Follicopeptide Gel Serum and strengthened liquidity through a directed share issue. Focus for 2026 is on expanding production, launching new products, and achieving balanced cash flow.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.